The quantitative measurement of liver function remains a Holy Grail of medicine. The absence of a reliable and readily available function test for the liver is in sharp contrast to organs such as the kidney (1) and lung (2) , for which such tests exist and are used in a wide variety of applications including prognostication and determination of the need for solid organ transplantation.
It is easy to see how such a test would have wide applicability in clinical practice. It would provide valuable prognostic information in the setting of cirrhosis, for which a histologic diagnosis that offers no information about liver function is often used as a surrogate to indicate (3)), this result may be because GEC is unlikely to change-even with significant impairment of liver volumebecause of the ability of the remaining healthy liver to effectively phosphorylate galactose. These data, if confirmed, could alter the ongoing effort to develop 18 F-labeled fluorogalactose for the measurement of GEC with PET (4). However, it will be more interesting to see if these results will change in the setting of preexisting hepatic fibrosis, which can be induced experimentally. The underestimation of liver generation by 99m Tc-GSA uptake may also reflect a component of liver function that may take longer to recover after hepatectomy, suggesting that 99m Tc-GSA uptake may indeed be of value in tracking liver function recovery more chronically. This possibility is suggested by the slow but sustained increase of liver function by day 7 after hepatectomy (Table 3 in de Graaf et al. (3)).
An interesting and previously reported finding is the development of mild to moderate steatosis after hepatectomy (5) . Although the exact determinants and implications of steatosis in this setting are not clear, previous studies have suggested a possible deleterious effect on indices of hepatic regeneration (6) . Whether the effect of steatosis differentially influences the performance of the tests used is unclear and would probably require a quantitative or semiquantitative assessment of triglyceride content in the liver-an assessment that would certainly be worth performing in the future.
In contrast to previous experiments using similar models (7), rats in the current study failed to return to their baseline liver volume. Whether the presence of steatosis, the experimental setup of overnight fasting, or other factors may have affected regeneration is fraught with controversy because fasting had been previously reported to favorably affect regeneration (8) . Nonetheless, it is certainly worth further exploration. Despite this impairment in volumetric regeneration, functional recovery appears to have been achieved. The causes for this discrepancy may indeed reflect the pitfalls of assessments of liver recovery after hepatectomy based purely on volume measurement. Conversely, the causes may indicate the limitations of using a single test for the assessment of function in an organ that performs an extremely wide array of metabolic and synthetic functions. Indeed, the de Graaf et al. (3) summarize the conundrum of liver function testing by stating that "each quantitative liver function test measures a distinct component of the broader liver function spectrum, which in turn may be differentially influenced during the regenerative process" (3).
In conclusion, the search for the Holy Grail continues, and although 99m Tc-mebrofenin HBS may indeed offer the advantage of providing measurement of both uptake and excretory function, the current study serves to illustrate the fact that volumetric, scintigraphic, and metabolic tests may complement one another in providing information on liver function and regeneration at different time points. The Holy Grail may not be a single test, after all, but a combination of complementary assessments. 
